LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Затворен

Сектор Здравеопазване

16.09 -0.62

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.97

Максимум

16.09

Ключови измерители
By Trading Economics
Приходи	17M 33M
Продажби	36M 242M
EPS	0.2
Марж на печалбата	13.797
Служители	597
EBITDA	12M 33M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+67.58 upside

Дивиденти
By Dow Jones
Следващи печалби	31.10.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	119M 2.7B
Предишно отваряне	16.71
Предишно затваряне	16.09

Настроения в новините

By Acuity

100%

340 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

15.69 / 16.33 Подкрепа & съпротива

ACADIA Pharmaceuticals Inc Графика

Свързани новини

6.09.2024 г., 22:41 ч. UTC

Пазарно говорене

KinderCare and StandardAero File for IPOs -- Market Talk

6.09.2024 г., 21:18 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6.09.2024 г., 21:05 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 20:39 ч. UTC

Печалби

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6.09.2024 г., 20:35 ч. UTC

Топ новини

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6.09.2024 г., 20:34 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6.09.2024 г., 20:11 ч. UTC

Топ новини

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6.09.2024 г., 19:51 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6.09.2024 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Gains -- Market Talk

6.09.2024 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6.09.2024 г., 19:01 ч. UTC

Пазарно говорене

Gold Slips on Prevailing Uncertainty -- Market Talk

6.09.2024 г., 18:27 ч. UTC

Топ новини

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6.09.2024 г., 18:25 ч. UTC

Пазарно говорене

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6.09.2024 г., 18:15 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6.09.2024 г., 18:12 ч. UTC

Топ новини

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6.09.2024 г., 17:44 ч. UTC

Пазарно говорене

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Пазарно говорене

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Топ новини

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6.09.2024 г., 17:27 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in August -- Market Talk

6.09.2024 г., 16:36 ч. UTC

Пазарно говорене

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6.09.2024 г., 16:35 ч. UTC

Печалби

Горещи акции

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6.09.2024 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Печалби

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

67.58% нагоре

12-месечна прогноза

Среден 26.93 USD 67.58%

Висок 39 USD

Нисък 17 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на ACADIA Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

15.69 / 16.33Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There are no events.

Настроение

By Acuity

340 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).